Literature DB >> 22161573

Particles in therapeutic protein formulations, Part 1: overview of analytical methods.

Sarah Zölls1, Ruedeeporn Tantipolphan, Michael Wiggenhorn, Gerhard Winter, Wim Jiskoot, Wolfgang Friess, Andrea Hawe.   

Abstract

The presence of particles is a major issue during therapeutic protein formulation development. Both proteinaceous and nonproteinaceous particles need to be analyzed not only due to the requirements of the Pharmacopeias but also to monitor the stability of the protein formulation. Increasing concerns about the immunogenic potential together with new developments in particle analysis make a comparative description of established and novel analytical methods useful. Our review aims to provide a comprehensive overview on analytical methods for the detection and characterization of visible and subvisible particles in therapeutic protein formulations. We describe the underlying theory, benefits, shortcomings, and illustrative examples for quantification techniques, as well as characterization techniques for particle shape, morphology, structure, and identity.
Copyright © 2011 Wiley Periodicals, Inc.

Mesh:

Substances:

Year:  2011        PMID: 22161573     DOI: 10.1002/jps.23001

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  22 in total

1.  Factors Governing the Precision of Subvisible Particle Measurement Methods - A Case Study with a Low-Concentration Therapeutic Protein Product in a Prefilled Syringe.

Authors:  Anacelia Ríos Quiroz; Jens Lamerz; Thierry Da Cunha; Adeline Boillon; Michael Adler; Christof Finkler; Joerg Huwyler; Roland Schmidt; Hanns-Christian Mahler; Atanas V Koulov
Journal:  Pharm Res       Date:  2015-10-16       Impact factor: 4.200

2.  Flow imaging microscopy for protein particle analysis--a comparative evaluation of four different analytical instruments.

Authors:  Sarah Zölls; Daniel Weinbuch; Michael Wiggenhorn; Gerhard Winter; Wolfgang Friess; Wim Jiskoot; Andrea Hawe
Journal:  AAPS J       Date:  2013-08-31       Impact factor: 4.009

Review 3.  High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.

Authors:  Rajoshi Chaudhuri; Yuan Cheng; C Russell Middaugh; David B Volkin
Journal:  AAPS J       Date:  2013-10-31       Impact factor: 4.009

4.  Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.

Authors:  Srivalli N Telikepalli; Ozan S Kumru; Cavan Kalonia; Reza Esfandiary; Sangeeta B Joshi; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2014-01-22       Impact factor: 3.534

5.  Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques.

Authors:  Cavan Kalonia; Ozan S Kumru; Jae Hyun Kim; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2013-10-09       Impact factor: 3.534

Review 6.  Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

Authors:  Satish K Singh; Donna L Luisi; Roger H Pak
Journal:  Pharm Res       Date:  2015-05-19       Impact factor: 4.200

7.  Evaluation of Nanoparticle Tracking for Characterization of Fibrillar Protein Aggregates.

Authors:  Dennis T Yang; Xiaomeng Lu; Yamin Fan; Regina M Murphy
Journal:  AIChE J       Date:  2014-04-01       Impact factor: 3.993

8.  Probing structurally altered and aggregated states of therapeutically relevant proteins using GroEL coupled to bio-layer interferometry.

Authors:  Subhashchandra Naik; Ozan S Kumru; Melissa Cullom; Srivalli N Telikepalli; Elizabeth Lindboe; Taylor L Roop; Sangeeta B Joshi; Divya Amin; Phillip Gao; C Russell Middaugh; David B Volkin; Mark T Fisher
Journal:  Protein Sci       Date:  2014-07-28       Impact factor: 6.725

9.  Phase-Appropriate Application of Analytical Methods to Monitor Subvisible Particles Across the Biotherapeutic Drug Product Life Cycle.

Authors:  Roman Mathaes; Linda Narhi; Andrea Hawe; Anja Matter; Karoline Bechtold-Peters; Sophia Kenrick; Sambit Kar; Olga Laskina; John Carpenter; Richard Cavicchi; Ellen Koepf; E Neil Lewis; Rukman De Silva; Dean Ripple
Journal:  AAPS J       Date:  2019-10-30       Impact factor: 4.009

10.  Nanoparticulate Impurities Isolated from Pharmaceutical-Grade Sucrose Are a Potential Threat to Protein Stability.

Authors:  Daniel Weinbuch; Mitchel Ruigrok; Wim Jiskoot; Andrea Hawe
Journal:  Pharm Res       Date:  2017-10-24       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.